ABSTRACT
INTRODUCTION
First-trimester screening for pre-eclampsia (PE) has been increasingly incorporated into clinical practice. The disease remains one of the main causes of maternal and perinatal morbidity and mortality, affecting 2-8% of pregnancies and more than 6 million women worldwide every year 1 . In the USA in 2012, the cost of PE within the first 12 months of delivery was estimated at $2.18 billion, borne disproportionately by births of low gestational age 2 . Furthermore, recent studies have shown a significant reduction in the prevalence of preterm PE with the use of low-dose aspirin (150 mg daily) initiated before 16 weeks' gestation 3, 4 , but there is limited evidence of benefit when this medication is started after 16 weeks 4 . Pre-eclampsia screening methods relying on maternal characteristics and medical history (maternal factors) alone have shown variable performance, with either a high false-positive rate (FPR) or poor detection rate 5 . Individual risk calculation based on logistic regression equations and Bayes' theorem, in turn, allows detection of more than 75% of cases of preterm PE, with a FPR of 10% [6] [7] [8] [9] . The Fetal Medicine Foundation (FMF) algorithm takes into account maternal characteristics, obstetric and medical history, mean arterial blood pressure (MAP), mean uterine artery (UtA) pulsatility index (PI) on Doppler ultrasound, and placental growth factor (PlGF) 7 . Algorithms published previously have also included pregnancy-associated plasma protein-A (PAPP-A) measurement 8 . These algorithms were developed in the UK and validated prospectively in different populations 6, 10 .
Screening methods that include measurement of biophysical and biochemical markers require regular monitoring and auditing, as systematic errors will inevitably impact on the screen-positive rate and, consequently, on the performance of the test 11 . To minimize bias, MAP and UtA-PI measurements should be performed by trained professionals using adequate equipment and following standardized procedures 12, 13 . Of the biophysical and biochemical parameters, UtA-PI is the one most at risk of systematic error since it is operator-dependent, whilst MAP, PAPP-A and PlGF are measured using automated devices calibrated at regular intervals. Feedback to operators has been shown to improve measurement performance and, in cases of systematic error, retraining of operators is recommended 14 . This study aimed to assess the quality of measurements of UtA-PI performed in an established first-trimester screening program for preterm PE.
METHODS

Study population
This study was performed as a quality assurance analysis in a screening program for PE and is part of a study in which pregnancy outcomes are currently being collected in order to validate and assess the performance of screening for PE in a large Australian cohort. Consecutive patients with a singleton pregnancy attending first-trimester aneuploidy screening between 11 + 0 and 13 + 6 weeks in a large prenatal ultrasound practice in Sydney, Australia, from May 2014 to February 2017, also had combined screening for preterm PE based on the FMF algorithm.
Procedure and data collection
Data collection was performed prospectively during the clinical visit for ultrasound and screening for PE. Maternal characteristics and medical and obstetric histories were recorded. MAP was measured using an automated device validated for use in pregnancy following a previously standardized technique 13 . Color Doppler ultrasound, preferably transabdominal, was used to measure left and right UtA-PI and the average value was recorded. All sonographers undertook instruction in the measurement of UtA-PI following a technique published previously 12 , and had at least 12 months of experience in measuring UtA-PI. Serum PlGF concentrations were measured using automated devices (DELFIA ® Xpress random access platform, PlGF 1-2-3™ kit, PerkinElmer/Wallac Oy, Turku, Finland; or B.R.A.H.M.S KRYPTOR compact PLUS platform ® , B.R.A.H.M.S PlGF Kryptor™ kit, Thermo Scientific, Hennigsdorf, Germany).
Results of all biomarkers were adjusted for maternal characteristics and expressed as multiples of the median (MoM), and individual operators were identified by initials only. Patient-specific risks for preterm PE were calculated using the FMF algorithm 8 . As this was a clinical audit of a validated screening program that did not identify patients directly and did not seek pregnancy outcome information, patient consent was not required. The study involved de-identified data for analysis and quality assurance purposes, and therefore ethical clearance was not required, as per the National Health and Medical Research Council (NHMRC) 2014 Ethical Considerations in Quality Assurance and Evaluation Activities 15 .
Statistical analysis
The main outcome measure was the proportion of sonographers measuring UtA-PI within ideal and acceptable ranges.
The distribution of UtA-PI MoM values was made Gaussian using logarithmic transformation. A forest plot was produced of each individual operator's mean UtA-PI MoM value on the logarithmic scale with their respective 95% CI. A central tendency and dispersion chart of the mean log 10 UtA-PI MoM value of each operator who carried out more than 50 examinations was also produced. Graphs were plotted in relation to the expected median UtA-PI MoMs of 1.0 ± 0.05 and 1.0 ± 0.1. UtA-PI MoM distributions were considered ideal when plotted in the interval 0.95-1.05 and acceptable when plotted in the interval 0.90-1.10. Temporal analyses were produced using monthly distributions and cumulative sum (CUSUM) charts.
Screen positive rates, using a risk cut-off of 1: 100 for preterm PE, were calculated and compared between sonographers obtaining a mean UtA-PI MoM value < 0.95, those obtaining one between 0.95 and 1.05 and those obtaining one >1.05 MoM, using the chi-square test. Logistic regression analysis was used to estimate the impact of UtA-PI measurement on the screen-positive rate.
Statistical analyses were performed using the software SPSS Statistics Version 25.0 (IBM Corp., Armonk, NY, USA).
RESULTS
In total, 21 010 women attended for assessment at 11 + 0 to 13 + 6 weeks' gestation and had screening for PE with complete data. The baseline characteristics of the study population are presented in Table 1 .
The overall median UtA-PI MoM was 1.042 (interquartile range (IQR), 0.852-1.260), which falls within the ideal interval of 0. (Figures 1a and 2a) . Measurements of UtA-PI were consistent during the study period (Figures 1b and 2b ) and across ethnic groups and categories of maternal weight. Examples of an operator with good distribution over time and one with systematic positive error are shown in Figure 3 .
The overall screen-positive rate for preterm PE, using a cut-off of 1:100, was 11.9%, similar to that published in previous studies 6, 9 . However, sonographers who carried out more than 50 examinations and obtained a mean UtA-PI MoM value < 0.95 (3/42, 7.1%) had a lower screen-positive rate (7.2%; 95% CI, 5.2-9.7%; P < 0.001), and those who obtained a mean UtA-PI MoM value >1.05 (15/42, 35.7%) had a higher screen-positive rate (13.2%; 95% CI, 12.5-14.0%; P < 0.001), when compared with those with a mean measurement in the ideal interval (24/42, 57.2%; screen-positive rate, 11.2%; 95% CI, 10.6-11.8%). Screen positive rate was independently influenced by UtA-PI after adjustment for MAP and PlGF values in logistic regression analysis (regression coefficient, 4.22; standard error, 0.11; adjusted odds ratio, 68.37; P < 0.001).
DISCUSSION
Main findings
Quality assurance is an indispensable requisite in screening programs 16 . This study demonstrates that UtA-PI is measured well by trained operators following a standardized procedure. In a large ultrasound clinic that provides first-trimester screening for PE routinely, more than 97% of sonographers who performed more than 50 examinations measured UtA-PI within acceptable limits.
As expected, sonographers with higher measurements of UtA-PI had a higher screen-positive rate. However, the majority of the sonographers with high measurements were only slightly above the expected median, and the increase in screen-positive rate, although statistically significant, was relatively small.
Study limitations
This was a cross-sectional evaluation that did not include the outcomes of the pregnancies studied. As such, we aimed to investigate the effect of variations in UtA-PI measurements at the time of screening and their impact on the screen-positive rate, which is an important step prior to externally validating and evaluating the performance of screening.
Nevertheless, the number of cases studied was large, and the finding that the overall median measurement of UtA-PI fell within the range considered ideal is reassuring, with small variations probably having very little effect, if any, on the performance of screening.
Clinical implications
UtA Doppler is an essential component of first-trimester combined screening for preterm PE and can be undertaken within a few minutes as part of the routine first-trimester ultrasound 5 . Logistic regression models that include multiple markers to calculate the probability of disease development, through Bayes' theorem, require continuous auditing of biomarker measurements. Similar to nuchal translucency audit in programs of first-trimester screening for chromosomal abnormalities, the measurement distributions of each operator should be as close as possible to the expected central value and indicate acceptable dispersion 17, 18 . While small variations from expected values are unlikely to be clinically significant, systematic error can potentially under-or overestimate the risk of PE, significantly changing the screen-positive rate 18 . Of all markers used for PE risk calculation, mean UtA-PI is the most operator dependent, which could lead to more concerning biases. MAP is generally measured with the use of automated devices validated for use in pregnancy, as are serum biomarkers, with rigorous quality control by the reagent providers.
This study included a large number of patients and sonographers and confirms that measurements of UtA-PI are reliable when measured by trained staff and following the recommended technique 19 in the clinical setting. According to the described technique, UtA-PI in the first trimester is ideally measured using transabdominal ultrasound, with the identification of the UtAs at the level of the internal cervical os in a parasagittal sonographic view, using a 2-mm gate and angle < 30 •19-21 . Measurements performed using a transvaginal examination may produce higher PI values 22, 23 , but this finding could not be reproduced in all studies [24] [25] [26] . Measurements obtained from distal segments of the UtA produce reduced PI values 21, 27 , whereas measurements inferior to the internal os (cervical branch) lead to increased values. Transvaginal ultrasound and measurements in different locations might be the reason why some sonographers overestimated UtA-PI.
A recent study has reported a novel technique to measure UtA-PI in the first trimester using a transverse view of the cervix and visualization of both UtAs at the level of the internal os at the same time rather than using the longitudinal view, and both techniques appear to be comparable 28 . Previous studies also suggest moderate intra-and interobserver reproducibility 23, 26 that increases with the experience of the sonographers 26 . Comparing experienced with inexperienced operators, Ridding et al.
14 found an increased screen-positive rate among inexperienced sonographers, as well as better performance within operators who received feedback on their measurements compared with those who did not. These findings highlight the importance not only of auditing and giving feedback, but also of retraining sonographers and reinforcing the use of the correct technique when significant and persistent deviations from the mean or median values are identified. Our finding that operators obtaining higher UtA-PI values have a higher screen-positive rate leads to the same conclusion.
A clear linear independent association between UtA-PI values in the first trimester and the risk of PE has been reported consistently in previous studies 7, 8, [29] [30] [31] . Hence, the fact that higher mean UtA-PI values will inevitably lead to an increased screen-positive rate is expected, if the other markers are held constant and assuming that they should not vary according to UtA-PI operators.
In conclusion, UtA Doppler is measured well by trained sonographers after implementation of first-trimester combined screening for PE in the clinical setting. A quality assurance process is essential to monitor mean values through time and maintain standards. The use of individual CUSUM charts may be useful in order to give personal feedback, and retraining professionals may be needed in cases of systematic and persistent error.
